A single-center observational study on the efficacy and safety of rituximab in adult patients with minimal change nephropathy

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054244

Enrollment

Unknown

Registered

2021-12-11

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal change nephropathy of adult

Interventions

Rituximab group:No

Glucocorticoid immunosuppressant group:No

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Primary nephrotic syndrome: 24-hour urine protein > 3.5 g, serum albumin less than 30 g/L; renal biopsy is diagnosed as MCD; 2. Aged > 18 years; 3. eGFR > 40 ml/min; 4. No history of using RTX.

Exclusion criteria

Exclusion criteria: 1. Combined with hepatitis B, C, HIV, etc.; 2. Allergic to this drug or murine protein; 3. Patients with severe active infection; 4. Patients with severely impaired immune response (such as low gamma globulin disease, severe CD4 or CD8 cell count reduction); 5. Patients with severe heart failure (NYHA grade IV); 6. Pregnancy, breastfeeding, or unreliable methods of contraception.

Design outcomes

Primary

Measure	Time frame
12-month urine protein complete remission and partial remission rate;	—

Secondary

Measure	Time frame
Renal function progression;Safety;Recurrence rate;	—

Countries

China

Contacts

Public ContactWan Qijun

Shenzhen Second People's Hospital

yiyuan2224@sina.com+86 13537857368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026